Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | NOS1 | P29475 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.49 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.49 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.49 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29697249 | 1.00 | PARP1 (0.51) | PARP1MAPTALDH1A1TDP1HPGD | |
| Sulfuric Acid SCHEMBL1405805 | 0.93 | PARP1 (0.46) | PARP1MAPTALDH1A1TDP1HPGD | |
| SCHEMBL266008 | 0.87 | MAPT (0.61) | PARP1MAPTALDH1A1TDP1HPGD | |
| SCHEMBL29672461 | 0.87 | MAPT (0.61) | PARP1MAPTALDH1A1TDP1HPGD | |
| Quinoline SCHEMBL27606941 | 0.83 | MAPT (0.46) | MAPTALDH1A1HPGDKDM4ECYP3A4 | |
| SCHEMBL29431208 | 0.81 | JAK2 (0.51) | PARP1MAPTALDH1A1TDP1HPGD | |
| SCHEMBL2931498 | 0.81 | JAK2 (0.51) | PARP1MAPTALDH1A1TDP1HPGD | |
| SCHEMBL30833662 | 0.81 | DAO (0.51) | PARP1MAPTALDH1A1TDP1HPGD | |
| SCHEMBL921416 | 0.81 | DAO (0.51) | PARP1MAPTALDH1A1TDP1HPGD | |
| SCHEMBL445096 | 0.80 | MAPT (0.50) | PARP1MAPTALDH1A1TDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118515615-A | Preparation method of 3-methyl-6-nitro-1H-indazole | 江西正梦新材料有限公司 | 2024-08-20 | — | — | CN | claimed |
| CN-103319410-B | A kind of synthetic method of indazole compound | TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH (CN) | 2016-04-06 | — | — | CN | claimed |
| CN-103319410-A | Synthesis method of indazole compound | TIANJIN INST PHARM RESEARCH | 2013-09-25 | — | — | CN | claimed |
| US-4978603-A | Developing an emulsion layer containing a rhodium salt and a preferential grain size using a dihydroxy developer, a sulfite and an indazole compound | FUJI PHOTO FILM CO., LTD. (JP) | 1990-12-18 | — | — | US | claimed |
| US-12606544-B2 | JAK1 selective kinase inhibitor | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2026-04-21 | — | — | US | disclosed |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| EP-4603488-A1 | NOVEL INDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | Korea University Research and Business Foundation (KR) | 2025-08-20 | — | — | EP | disclosed |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | ARTIOS PHARMA LIMITED (GB) | 2025-07-15 | — | — | US | disclosed |
| CN-120035587-A | Novel indazole derivative or pharmaceutically acceptable salt thereof and use thereof | 高丽大学校产学协力团 | 2025-05-23 | — | — | CN | disclosed |
| EP-3956322-B1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025096710-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-119684264-A | Preparation method of pazopanib hydrochloride | 浙江乐普药业股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| EP-0306833-B1 | Silver halide photographic material | FUJI PHOTO FILM CO LTD (JP) | 1994-01-12 | — | — | EP | disclosed |
| US-5220026-A | Antitumor agents | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1993-06-15 | — | — | US | disclosed |
| EP-0487097-A1 | Pyrazoloacridone derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1992-05-27 | — | — | EP | disclosed |
| US-5079358-A | Humans; leukemia | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1992-01-07 | — | — | US | disclosed |
| US-4978603-A | Developing an emulsion layer containing a rhodium salt and a preferential grain size using a dihydroxy developer, a sulfite and an indazole compound | FUJI PHOTO FILM CO., LTD. (JP) | 1990-12-18 | — | — | US | disclosed |
| US-4956263-A | BLACKAND WHITE PHOTOGRAPHIC FILM CONTAINING CONTAINING A HYDRAZINE DERIVATIVE; HIGH CONTRAST; DAYLIGHT USE; ANTISOILANTS; SAFELIGHT SAFETY | FUJI PHOTO FILM CO., LTD. (JP) | 1990-09-11 | — | — | US | disclosed |
| EP-0347749-A2 | Pyrazoloacridone derivatives with anti-tumoral activity | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1989-12-27 | — | — | EP | disclosed |
| US-4221857-A | DEVELOPER COMPRISING SULFITE ION, A DIHYDROXYBENZENE, AND A HYDRAZIDE COMPOUND | FUJI PHOTO FILM CO., LTD. (JP) | 1980-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606544-B2 | JAK1 selective kinase inhibitor | JAK1, JAK2, JAK3 | PARP1 2480/4885MAPT 4828/4885ALDH1A1 1845/4885 |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | ABL1, TH, CYP3A43 | PARP1 2792/4885MAPT 3633/4885ALDH1A1 1008/4885 |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | SDHA, DPYD, TP53 | PARP1 284/4885MAPT 4249/4885ALDH1A1 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.